Opin vísindi

Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland

Skoða venjulega færslu

dc.contributor Landspitali - The National University Hospital of Iceland
dc.contributor.author Hjálmarsdóttir, Martha Ásdís
dc.contributor.author Haraldsson, Gunnsteinn Ægir
dc.contributor.author Quirk, Sigríður Júlía
dc.contributor.author Haraldsson, Ásgeir
dc.contributor.author Erlendsdóttir, Helga
dc.contributor.author Kristinsson, Karl Gústaf
dc.date.accessioned 2022-08-26T01:02:46Z
dc.date.available 2022-08-26T01:02:46Z
dc.date.issued 2020
dc.identifier.citation Hjálmarsdóttir , M Á , Haraldsson , G Æ , Quirk , S J , Haraldsson , Á , Erlendsdóttir , H & Kristinsson , K G 2020 , ' Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland ' , PLoS ONE , vol. 15 , no. 3 , e0230332 . https://doi.org/10.1371/journal.pone.0230332
dc.identifier.issn 1932-6203
dc.identifier.other 37864002
dc.identifier.other 1ba1ba0b-3d6a-4d5a-a259-b950eaa772a2
dc.identifier.other 85081889216
dc.identifier.other 32182260
dc.identifier.uri https://hdl.handle.net/20.500.11815/3358
dc.description Funding: This work is an investigator-initiated study that was supported by grants from: - The Landspítali University Hospital Research Fund (MÁH) https://www.landspitali.is - GlaxoSmithKline Biologicals SA (KGK, HE, ÁH), https://www.gsk.com The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing interests: This work is an investigator-initiated study that was supported by grants from: - The Landspítali University Hospital Research Fund (MÁH) https://www.landspitali.is - GlaxoSmithKline Biologicals SA https://www.gsk.com The authors declare that this does not alter our adherence to PLOS ONE policies on sharing data and materials. Neither GlaxoSmithKline Biologicals SA, nor Landspítali University Hospital Research Fund had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: Copyright: © 2020 Hjálmarsdóttir et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.description.abstract Background Penicillin non-susceptible (PNSP) and multi-resistant pneumococci have been prevalent in Iceland since early nineties, mainly causing problems in treatment of acute otitis media. The 10-valent protein conjugated pneumococcal vaccine (PHiD-CV) was introduced into the childhood vaccination program in 2011. The aim of the study was to investigate the changes in antimicrobial susceptibility and serotype distribution of penicillin non-susceptible pneumococci (PNSP) in Iceland 2011-2017. Methods and findings All pneumococcal isolates identified at the Landspítali University Hospital in 2011-2017, excluding isolates from the nasopharynx and throat were studied. Susceptibility testing was done according to the EUCAST guidelines using disk diffusion with chloramphenicol, erythromycin, clindamycin, tetracycline, trimethoprim/sulfamethoxazole and oxacillin for PNSP screening. Penicillin and ceftriaxone minimum inhibitory concentrations (MIC) were measured for oxacillin resistant isolates using the E-test. Serotyping was done using latex agglutination and/or multiplex PCR. The total number of pneumococcal isolates that met the study criteria was 1,706, of which 516 (30.2%) were PNSP, and declining with time. PNSP isolates of PHiD-CV vaccine serotypes (VT) were 362/516 (70.2%) declining with time, 132/ 143 (92.3%) in 2011 and 17/54 (31.5%) in 2017. PNSP were most commonly of serotype 19F, 317/516 isolates declining with time, 124/143 in 2011 and 15/54 in 2017. Their number decreased in all age groups, but mainly in the youngest children. PNSP isolates of non PHiD-CV vaccine serotypes (NVT) were 154/516, increasing with time, 11/14, in 2011 and 37/54 in 2017. The most common emerging NVTs in 2011 and 2017 were 6C, 1/143 and 10/ 54 respectively. Conclusions PNSP of VTs have virtually disappeared from children with pneumococcal diseases after the initiation of pneumococcal vaccination in Iceland and a clear herd effect was observed. This was mainly driven by a decrease of PNSP isolates belonging to a serotype 19F multiresistant lineage. However, emerging multi-resistant NVT isolates are of concern.
dc.format.extent 1234084
dc.format.extent
dc.language.iso en
dc.relation.ispartofseries PLoS ONE; 15(3)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Sýklalyfjaónæmi
dc.subject Bóluefni
dc.subject General Biochemistry,Genetics and Molecular Biology
dc.subject General Agricultural and Biological Sciences
dc.subject Multidisciplinary
dc.title Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal vaccine in Iceland
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article
dc.description.version Peer reviewed
dc.identifier.doi 10.1371/journal.pone.0230332
dc.relation.url http://www.scopus.com/inward/record.url?scp=85081889216&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine
dc.contributor.department Clinical Laboratory Services, Diagnostics and Blood Bank
dc.contributor.department Women's and Childrens's Services


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu